102 related articles for article (PubMed ID: 19407573)
41. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
[TBL] [Abstract][Full Text] [Related]
42. Prevention of chemotherapy-induced neutropenia by special honey intake.
Zidan J; Shetver L; Gershuny A; Abzah A; Tamam S; Stein M; Friedman E
Med Oncol; 2006; 23(4):549-52. PubMed ID: 17303914
[TBL] [Abstract][Full Text] [Related]
43. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
44. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
45. Canadian oncologists and clinical practice guidelines: a national survey of attitudes and reported use. Provincial Lung Disease Site Group of Cancer Care Ontario.
Graham ID; Evans WK; Logan D; O'Connor A; Palda V; McAuley L; Brouwers M; Harrison MB
Oncology; 2000 Nov; 59(4):283-90. PubMed ID: 11096339
[TBL] [Abstract][Full Text] [Related]
46. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
Eisenkop SM; Spirtos NM
Gynecol Oncol; 2001 Sep; 82(3):489-97. PubMed ID: 11520145
[TBL] [Abstract][Full Text] [Related]
47. Induction of white cell proliferation due to haematopoietic growth factors is associated with an increase in multiple forms of dihydrofolate reductase in non-neutropenic cancer patients.
Iqbal MP; Burney IA; Sultana F; Mehboobali N
J Pak Med Assoc; 2001 Feb; 51(2):68-71. PubMed ID: 11321874
[TBL] [Abstract][Full Text] [Related]
48. Perception and use of complementary and alternative medicine among gynecologic oncology care providers.
Rhode JM; Patel DA; Sen A; Schimp VL; Johnston CM; Liu JR
Int J Gynaecol Obstet; 2008 Nov; 103(2):111-5. PubMed ID: 18760411
[TBL] [Abstract][Full Text] [Related]
49. Granulocyte colony-stimulating factor use in cancer patients.
Baker J; McCune JS; Harvey RD; Bonsignore C; Lindley CM
Ann Pharmacother; 2000; 34(7-8):851-7. PubMed ID: 10928394
[TBL] [Abstract][Full Text] [Related]
50. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.
Dewdney SB; Rimel BJ; Reinhart AJ; Kizer NT; Brooks RA; Massad LS; Zighelboim I
Gynecol Oncol; 2010 Oct; 119(1):18-21. PubMed ID: 20673970
[TBL] [Abstract][Full Text] [Related]
51. Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors.
Calatayud S; Warner TD; Breese EJ; Mitchell JA
Br J Pharmacol; 2001 Nov; 134(6):1237-44. PubMed ID: 11704643
[TBL] [Abstract][Full Text] [Related]
52. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y
J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373
[TBL] [Abstract][Full Text] [Related]
53. Gynecologic Oncologist Views Influencing Referral to Outpatient Specialty Palliative Care.
Hay CM; Lefkowits C; Crowley-Matoka M; Bakitas MA; Clark LH; Duska LR; Urban RR; Chen LM; Creasy SL; Schenker Y
Int J Gynecol Cancer; 2017 Mar; 27(3):588-596. PubMed ID: 28060140
[TBL] [Abstract][Full Text] [Related]
54. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
Kaplan DE; Mehta R; D'Addeo K; Valderrama A; Taddei TH;
Medicine (Baltimore); 2018 Jan; 97(4):e9757. PubMed ID: 29369224
[TBL] [Abstract][Full Text] [Related]
55. Use and toxicity of the colony-stimulating factors.
Schriber JR; Negrin RS
Drug Saf; 1993 Jun; 8(6):457-68. PubMed ID: 7687134
[TBL] [Abstract][Full Text] [Related]
56. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
[TBL] [Abstract][Full Text] [Related]
57. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
58. Is chemotherapy dose intensity adequate in breast cancer management in the Australian healthcare setting: a retrospective analysis.
Bae S; Yeung Y; Ng S; Craike M; Livingston PM; Chirgwin J
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e54-62. PubMed ID: 22989364
[TBL] [Abstract][Full Text] [Related]
59. Impact of Oncologists' Attitudes Toward End-of-Life Care on Patients' Access to Palliative Care.
Hui D; Cerana MA; Park M; Hess K; Bruera E
Oncologist; 2016 Sep; 21(9):1149-55. PubMed ID: 27412394
[TBL] [Abstract][Full Text] [Related]
60. Survey of US gynecologic oncologists finds that approximately 64% have experienced sexual harassment.
Printz C
Cancer; 2019 Nov; 125(21):3691. PubMed ID: 31603545
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
